Home›Clinical trials›A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight
Not yet recruiting · NCT07357766

A study testing whether a study medicine from Novo Nordisk, cagrisema, can help with weight.

What this means for you

Who can join
Adults 18+, are overweight, BMI 27+.
What you take
cagrisema, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.
How long it lasts
The full study runs about 1.6 years; your own time in it is usually shorter.
What you get
The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.
Phase Phase 3Sponsor Novo Nordisk A/SDrug cagrisemaClass OtherSites 26 USEnrollment target 1,400

What this study is for

Primary condition: Overweight. Also studied in: Obesity.

Full scientific study title: A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight.

Who can join

Age18 and upSexAnyBMI27 or higher

Adults 18+, are overweight, BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

  • Male or female (sex at birth)
  • Age 18 years or above at the time of signing the informing consent.
  • Body Mass Index (BMI) is greater than or equal to (>= ) 30.0 kilograms per square metre (kg/m^2) or BMI >= 27.0 kg/m^2 with the presence of at least one obesity-related complication including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease.

Key exclusion criteria

  • Glycosylated haemoglobin (HbA1c) >= 6.5 % (48 millimoles per mole [mmol/mol]) as measured by the central laboratory at screening.
  • History of type 1 or type 2 diabetes.
  • Previous exposure to CagriSema in a clinical study.

Where this study is enrolling

This trial has 26 sites across 16 states. Contact a site coordinator directly to start screening.

Alabama2 sites
  • Uni of Alabama at Birmingham
    Birmingham, Alabama
  • Cahaba Research
    Pelham, Alabama
California3 sites
  • Advanced Investigative Medicine, Inc.
    Hawthorne, California
  • Southern Cal Clinical Research
    Santa Ana, California
  • Encompass Clinical Research_Spring Valley
    Spring Valley, California
Connecticut1 site
  • Chase Medical Research LLC
    Waterbury, Connecticut
Florida3 sites
  • NextPhase Research
    Hollywood, Florida
  • Oceane 7 Medical & Research Center, Inc.
    Miami, Florida
  • ForCare Clinical Research
    Tampa, Florida
Georgia2 sites
  • EBGS Clinical Research Center, LLC
    Snellville, Georgia
  • Rophe Adult & Pediatric Medicine
    Union City, Georgia
Idaho1 site
  • Rocky Mountain Diabetes and Osteoporosis Center
    Idaho Falls, Idaho
Illinois1 site
  • PGM Research of Christie Clinic
    Champaign, Illinois
Michigan1 site
  • Arcturus HC PLC Troy Med Res
    Troy, Michigan
Mississippi1 site
  • Anointed Nephrology & HTN, LLC
    Brookhaven, Mississippi
Nevada2 sites
  • Palm Research Center Inc.
    Las Vegas, Nevada
  • Palm Research Center Inc.
    Las Vegas, Nevada
New York1 site
  • Weill Medical College of Cornell University
    New York, New York
Oklahoma1 site
  • Alliance for Multispecialty Research
    Norman, Oklahoma
South Carolina2 sites
  • Tribe Clinical Research LLC
    Greenville, South Carolina
  • Walker Family Care
    Little River, South Carolina
Texas3 sites
  • Elligo Clin Res Centre
    Austin, Texas
  • University of Texas Southwestern Medical Center
    Dallas, Texas
  • Forefront Med Res Inst PLLC
    Harlingen, Texas
Virginia1 site
  • TPMG Clinical Research
    Newport News, Virginia
Washington1 site
  • Capital Clin Res Ctr,LLC
    Olympia, Washington

Timeline

Started enrolling: 2026-06-22. Expected completion: 2028-01-17. Last updated on ClinicalTrials.gov: 2026-02-25.

Official source

We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, editor of GLP Chart
John Samaras, Founder and editorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas. About this site · LinkedIn · Contact
Why you can trust GLP ChartSame scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page weekly.